Furthermore, siRNA knockdowns of total PIK3CD variants, PIK3CD-L and PIK3CD-S showed differential inhibitory effects on AKT/mTOR signaling, possibly due to the differential S/L ratios in different cancer cell lines. This evidence concerns the gene AKT1 and cancer.